Engerix-B Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Engerix-B market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to the increasing prevalence of hepatitis B, expanding government vaccination programs, heightened awareness of hepatitis B, improvements in healthcare infrastructure, and the rise in global travel and migration.

The projected growth during the forecast period can be attributed to expanding vaccine access in emerging markets, government-backed immunization initiatives, a growing emphasis on preventive healthcare and vaccination, and increasing awareness of chronic hepatitis B. Key trends during this period include a high adoption of combination vaccines, the increasing use of digital health technologies for vaccine administration, the development of innovative delivery systems, mass immunization initiatives by government bodies, and rising government policies, initiatives, and awareness programs.

The growing prevalence of hepatitis B virus (HBV) infection is expected to drive the expansion of the Engerix-B market. Hepatitis B is a serious liver infection caused by the HBV, which can lead to chronic liver disease, liver damage, and an increased risk of liver cancer. Factors such as unprotected sexual contact, blood-to-blood transmission, lack of vaccination, and weakened immune systems contribute to the spread of HBV. Engerix-B contains a non-infectious form of the HBV surface antigen, which stimulates the immune system to protect against the virus. This vaccine provides long-lasting immunity, reducing the risk of infection and its associated complications. For example, in November 2023, the New York State Department of Health reported that 1,984 new hepatitis B cases were recorded in 2022, an 11% increase in chronic hepatitis B cases compared to 2021. As a result, the rising prevalence of HBV infection is driving the growth of the Engerix-B market.

Rising healthcare expenditure is expected to play a significant role in driving the growth of the Engerix-B market. Healthcare spending covers the total cost of medical services, goods, and treatments across both public and private sectors. Factors such as an aging population, which increases demand for healthcare services, and the costs associated with chronic and age-related conditions, contribute to higher healthcare expenditures. This growing spending supports the availability and accessibility of vaccines such as Engerix-B by funding vaccination programs, strengthening healthcare infrastructure, and ensuring vaccines remain affordable. This investment helps to reduce long-term costs related to treating hepatitis B and its complications. For instance, the Office for National Statistics reported in May 2024 that healthcare expenditure rose by 5.6% from 2022 to 2023, compared to a growth rate of just 0.9% the previous year. Consequently, the increase in healthcare expenditure is driving the growth of the Engerix-B market.

The rise in travel and migration is also expected to boost the growth of the Engerix-B market. Migration and travel involve the movement of people for various reasons, including employment, leisure, education, and resettlement. This trend is growing due to factors such as economic opportunities, family reunification, and environmental changes. Engerix-B provides vital protection against hepatitis B for travelers and migrants, especially those visiting high-risk regions. The vaccine helps reduce the risk of infection from exposure to contaminated blood, needles, or bodily fluids, making travel and migration safer. For example, in May 2024, the Office for National Statistics reported that the UK saw 38 million visits in 2023, a 6.7 million increase from the previous year. Additionally, the number of trips made by UK residents abroad rose from 71 million in 2022 to 86.2 million in 2023. Therefore, the increasing travel and migration are contributing to the growth of the Engerix-B market.

The key player in the engerix-B market is GlaxoSmithKline plc.

North America was the largest region in the engerix-B market in 2024. The regions covered in engerix-B report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the engerix-B market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Engerix-B is a vaccine that provides protection against hepatitis B, a serious liver infection caused by the hepatitis B virus (HBV). The vaccine contains hepatitis B surface antigen (HBsAg), a protein derived from the virus, which stimulates the body’s immune system to produce antibodies without causing the disease itself.

The main indications for Engerix-B include the prevention of hepatitis B virus (HBV) infection, prevention of chronic hepatitis B, protection for healthcare workers and high-risk populations, and post-exposure prophylaxis. The vaccine works by stimulating the immune system to produce antibodies, offering long-term immunity for individuals at risk of HBV. Engerix-B is distributed through various channels such as hospitals, clinics, vaccination centers, and pharmacies. It is used by a variety of end users, including private healthcare providers, long-term care facilities, and educational institutions.

The engerix-B market research report is one of a series of new reports that provides engerix-B market statistics, including the engerix-B industry global market size, regional shares, competitors with the engerix-B market share, detailed engerix-B market segments, market trends, and opportunities, and any further data you may need to thrive in the engerix-B industry. This engerix-B market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The engerix-B market consists of sales of adjuvants, buffering agents, and excipients. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.